Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese male or female participants, greater than or equal to (≥) 18 years of age~* Histologically confirmed metastatic melanoma (surgically unresectable Stage IIIC or Stage IV, American Joint Committee on Cancer)~* Treatment-naïve or having received prior systemic treatments for metastatic melanoma~* Positive BRAF V600 mutation result determined by a designated laboratory using the Cobas 4800 BRAF V600 Mutation Test~* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1~* Previous allowed chemotherapy, immunotherapy, or radiation therapy must have been completed at least 2 weeks prior to study drug administration, and all associated toxicity must be resolved (to less than or equal to \[≤\] Grade 1 or baseline)~* Recovery from effects of any major surgery (excluding tumor biopsy at baseline) or significant traumatic injury at least 14 days before the first dose of study treatment~* Adequate hematologic, renal, and liver function as defined by protocol~* Fertile men and women must use an effective method of contraception during treatment and for ≥6 months after completion of treatment as directed by their physician (in accordance with local requirements).~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy greater than (\>) 3 months~* Able to swallow pills~Exclusion Criteria:~* Active central nervous system (CNS) lesions (radiographically unstable/symptomatic lesions), except participants treated with stereotactic therapy or surgery who remain without evidence of disease progression in brain for ≥3 months and have been off corticosteroid and anticonvulsant therapy for ≥3 weeks~* History of or known spinal cord compression or carcinomatous meningitis~* Anticipated or ongoing administration of anti-cancer therapies other than those administered in this study~* Active squamous cell carcinoma (SCC) that has not been excised or has not yet adequately healed post excision~* Pregnant or lactating women~* Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate vemurafenib absorption~* Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, serious cardiac arrhythmia requiring medication, uncontrolled hypertension, cerebrovascular accident or transient ischemic attack, or symptomatic pulmonary embolism~* Known clinically significant active infection~* History of allogeneic bone marrow transplantation or organ transplantation~* Previous malignancy within the past 5 years other than adequately treated basal cell carcinoma or SCC of the skin, melanoma in-situ, and carcinoma in-situ of the cervix and/or curatively treated cancer from which the participant is currently disease-free, or any malignancy from which the participant has been continuously disease-free for at least 5 years~* Previous treatment with a BRAF inhibitor (sorafenib allowed) or MEK inhibitor~* Participants who have had one or more doses of vemurafenib in a previous clinical trial~* Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness, or hepatitis B virus or hepatitis C virus (HCV) carriers (hepatitis B surface antigen-positive, HCV antibody-positive)~* Received any investigational treatment within 4 weeks of study drug start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vemurafenib: Pharmacokinetic Cohort (Type: EXPERIMENTAL): Participants will receive vemurafenib orally as 960 mg twice daily on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and from Day 28 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
- Vemurafenib: Expansion Cohort (Type: EXPERIMENTAL): Participants will receive vemurafenib orally as 960 mg twice daily from Day 1 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.

Based on this trial design, predict the completion outcome and termination type (if applicable).